News and insights

Stanley Center director Steve Hyman talks about a new report he co-authored that explores the obstacles in developing new treatments and how to overcome them

Bill Sellers, head of Broad’s Cancer Program, talks about how to discover new classes of genetic dependencies that could move therapies closer to curing cancer patients.

By adapting virus-like particles to carry the machinery for a type of gene editing called prime editing, scientists have corrected disease-causing mutations in animals and increased editing efficiency.

Researchers have evolved the editing machine at the heart of the prime editing system, which can make a wide range of changes to the genome.

A new screening method zeroes in on adeno-associated viruses that enter the brain through a defined mechanism.

A one-time genome-editing treatment restores motor function and extends lifespan in an animal model of a neuromuscular disease that is the leading genetic cause of infant mortality.

With further development, the programmable system could be used in a range of applications including gene therapy and cancer therapy.

An unbiased protein analysis comparing synapses from people with the disorders uncovers shared patterns.

A study of a genetic mouse model of schizophrenia supports two long-debated hypotheses, and unveils additional new clues about the biological roots of the disorder.

Scientists uncover mutations that allow Salmonella to fly under the immune system’s radar for years

Physician-scientist Roby Bhattacharyya uses genomics and his experiences treating patients to study how “superbugs” evade drugs and find better ways to combat these dangerous pathogens.

A study of respiratory syncytial virus genomes reveals that multiple lineages were circulating within the United States last fall, rather than one highly transmissible variant.

Researchers at Broad and MIT report the first injectable “priming agents” for liquid biopsy, which increased circulating tumor DNA by more than 10-fold in mice.

The small molecule, now in clinical trials, increases activity of immune cells and sensitivity of tumors to immune attack.

Efforts to probe the entire genome of cancer cells in animals have led to potential new drugs — now in early-stage clinical trials — that could make cancer immunotherapy more effective for more patients.

By integrating clinical, genetic, and other data from patients with lung cancer, researchers identify biological factors that could help predict treatment outcomes.

A study of tumor exomes reconstructs a timeline of mutations for certain cancer types, revealing insight into the order of genetic drivers of the disease.

An analysis of nearly 11,000 human cancers revealed how large chromosomal changes, called aneuploidies, can promote or slow the growth of tumors.

Researchers identify protein modifications that underlie many key cancer processes.